Atezolizumab and Hyaluronidase-tqjs
Atezolizumab and hyaluronidase-tqjs is a type of targeted therapy drug called an immune checkpoint inhibitor. Atezolizumab is a monoclonal antibody that works by binding to the protein PD-L1 on the surface of some cancer cells, which keeps cancer cells from suppressing the immune system. This allows the immune system to attack and kill the cancer cells. Hyaluronidase is a recombinant human form of an enzyme that breaks down a substance in the body called hyaluronic acid. This increases the absorption of drugs into tissue. Atezolizumab and hyaluronidase-tqjs is a form of atezolizumab that is given as an injection under the skin. This form can be given in less time than atezolizumab, which is given through a vein.
FDA label information for this drug is available at DailyMed.
Use in Cancer
Atezolizumab and hyaluronidase-tqjs is approved to be used alone or with other drugs to treat adults with:
- Alveolar soft part sarcoma that has spread to other parts of the body or cannot be removed by surgery.
- Hepatocellular carcinoma (a type of liver cancer) that has spread to other parts of the body or cannot be removed by surgery. It is used with bevacizumab in adults who have not received systemic therapy.
- Melanoma that has a certain mutation in the BRAF gene. Atezolizumab and hyaluronidase-tqjs is used with cobimetinib fumarate and vemurafenib in adults whose cancer has spread to other parts of the body or cannot be removed by surgery.
- Non-small cell lung cancer. Atezolizumab and hyaluronidase-tqjs is used:
- alone after surgery and platinum chemotherapy in adults with stage IIA, stage IIB, or stage IIIA cancer that has the PD-L1 protein
- alone as the first treatment in adults whose cancer has spread to other parts of the body, has the PD-L1 protein, and does not have a mutation in the EGFR gene or ALK gene
- with bevacizumab, paclitaxel, and carboplatin or paclitaxel albumin-stabilized nanoparticle formulation and carboplatin as the first treatment in adults with non-squamous cancer that does not have a mutation in the EGFR gene or ALK gene that has spread to other parts of the body
- with paclitaxel albumin-stabilized nanoparticle formulation and carboplatin as the first treatment in patients with non-squamous cancer that does not have an abnormal EGFR gene or ALK gene and has spread to other parts of the body
- alone in adults whose cancer has spread to other parts of the body and got worse during or after treatment with platinum chemotherapy. For patients whose cancer has a mutation in the EGFR gene or ALK gene, atezolizumab is used if their cancer has gotten worse after treatment with FDA-approved therapy for these mutations.
- Small cell lung cancer. Atezolizumab and hyaluronidase-tqjs is used with carboplatin and etoposide as the first treatment in adults with extensive-stage cancer.
For information about atezolizumab that may apply to atezolizumab and hyaluronidase-tqjs, see the Drug Information Summary for Atezolizumab.
Atezolizumab and hyaluronidase-tqjs is also being studied in the treatment of other types of cancer.
More About Atezolizumab and Hyaluronidase-tqjs
Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
Research Results and Related Resources
Targeted Therapy to Treat Cancer
Clinical Trials Accepting Patients
Find Clinical Trials for Atezolizumab And Hyaluronidase-tqjs - Check for trials from NCI's list of cancer clinical trials now accepting patients.